Cerus Stock Price, News & Analysis

Cerus Corporation (Nasdaq: CERS) has secured an additional $7.2 million contract amendment from the U.S. Department of Defense (DoD) to advance the development of lyophilized INTERCEPT Fibrinogen Complex (LyoIFC) for treating trauma-related bleeding. This supplements their existing $18 million DoD contract for developing room-temperature, shelf-stable LyoIFC.

The new funding will support the CRYO-FIRST study, a 320-patient randomized trial comparing pre-thawed IFC to conventional cryoprecipitated antihemophilic factor in trauma patients with hemorrhagic shock. The study aims to evaluate the effectiveness of early fibrinogen administration in trauma patients and will begin enrollment in early 2026.

Since receiving initial DoD funding in November 2022, Cerus has achieved key milestones including FDA pathway discussions, successful process scale-up, and prototype delivery to the DoD.

Cerus Corporation (Nasdaq: CERS) announced progress in its European regulatory review for the INTERCEPT Red Blood Cells (RBC) system. The company's Notified Body, TÜV-SÜD, has completed reviewing the clinical module of the CE Mark submission and transferred information to the Czech Republic's State Institute for Drug Control (SÚKL).

The clinical module includes positive results from the U.S. Phase 3 ReCePI trial, expanding the CE Mark submission to cover all patient indications for RBC transfusion. SÚKL will now review the API module before TÜV-SÜD conducts manufacturing facility audits for final CE Mark decision.

Cerus Corporation (CERS) is commemorating World Blood Donor Day 2025 on June 14th, themed 'Give blood, give hope: together we save lives.' The company, which develops pathogen reduction technologies for blood components, emphasizes the critical role of blood donors in global healthcare. CEO Obi Greenman highlighted that over 118.5 million blood donations are collected annually worldwide, with 40% coming from high-income countries representing only 16% of the global population. The company hosted a blood drive at its headquarters to support local blood product availability. Blood transfusions serve various patient groups, including those undergoing cardiovascular surgery, transplants, trauma care, and cancer treatment.

Cerus Corporation (CERS) announced its management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, Florida. The presentation is scheduled for Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. Investors and interested parties can access a live webcast of the presentation through the Events & Presentation section on Cerus' Investor Relations website at ir.cerus.com. A replay of the webcast will remain available on the company's Investor Relations website for 30 days following the event.

Cerus Corporation (CERS) will present clinical data for its INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan from May 31 to June 4, 2025. The presentations will highlight data on the system's applications for platelets, plasma, cryoprecipitated fibrinogen complex, and red blood cells.

Key presentations include positive results from the Phase 3 ReCePI study in red blood cells, INTERCEPT treated cold stored platelets, and effective inactivation of California encephalitis virus. The event features a Cerus-sponsored symposium focusing on INTERCEPT's impact on adverse events, platelet use, and inventory management in France, along with its safety in neonates.

Multiple oral and poster presentations will cover topics including cold-stored platelet concentrates, reduced hemoglobin use in cardiac surgery, and pathogen reduction effectiveness.

Cerus Corporation (CERS) has secured regulatory approvals from French ANSM and Swiss Swissmedic for its INT200, a next-generation LED-based illumination device for the INTERCEPT Blood System. The INT200 features significant improvements over its predecessor, including a vertical configuration that allows three devices to fit in the space of one INT100, touch screen navigation, improved tray design, intelligent scanning, and custom reporting. This follows the CE Mark authorization received in March. Both France and Switzerland have been using INTERCEPT Blood System for all platelet components since 2018 and 2011 respectively. Cerus plans to convert its EMEA INT100 installed base to INT200s over the next three years and aims to submit a PMA to the FDA during 2026.

Cerus Corporation (CERS) reported strong Q1 2025 financial results with total revenue of $48.9M, up 13% year-over-year. Product revenue reached $43.2M, also up 13%, while government contract revenue was $5.6M. The company's INTERCEPT Fibrinogen Complex (IFC) showed significant growth with Q1 revenue of $3.0M compared to $1.9M in the prior year. Notable achievements include receiving CE Mark for INT200, their next-generation LED-based illumination device, and submitting an updated CE Mark application for the INTERCEPT red blood cell system. The company reported a net loss of $7.7M ($0.04 per share), improved from $9.7M loss year-over-year. With $80.9M in cash and equivalents, Cerus maintains its 2025 product revenue guidance of $194-200M. North American revenue grew 22%, while EMEA declined 4% due to forex impact.

Cerus (CERS) has scheduled the release of its first quarter 2025 financial results for Thursday, May 1, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss financial performance and provide business updates.

Management will present detailed financial results and offer a general business overview and outlook during the call. A replay of the event will be accessible on Cerus' website until May 22, 2025.

Cerus (CERS) has received CE mark approval for its next-generation LED-based illumination device (INT200) for the INTERCEPT Blood System for platelets and plasma under the EU Medical Device Regulation (MDR). This approval enables Cerus to market the INT200 throughout the European Union and regions recognizing CE mark certification.

The INT200 represents a significant upgrade featuring enhanced physical design and new software interface while maintaining compatibility with existing processing sets. This approval completes the authorization of the INTERCEPT Blood System for both platelets and plasma within the EU MDR framework, following the 2023 CE mark approvals of INTERCEPT processing sets.

The CE mark represents the first regulatory approval for Cerus' next-generation illuminator, with additional regulatory submissions planned over coming years. The INT200 will serve as the foundation for geographic expansion and future growth of the INTERCEPT business.